ROGER D GINGRICH, MD
Osteopathic Medicine at Hawkins Dr, Iowa City, IA
License number
Iowa 20912
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Iowa 20912
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
200 Hawkins Dr, Iowa City, IA 52242
Phone
(319) 356-3425
(319) 353-8377 (Fax)
(319) 353-8377 (Fax)
Professional information
Dr. Roger D Gingrich, Iowa City IA - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
(319) 384-8442 (Phone), (319) 384-7345 (Fax)
200 Hawkins Dr, Iowa City 52242
(319) 384-8442 (Phone), (319) 384-7345 (Fax)
Certifications:
Internal Medicine, 1977, Medical Oncology, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
UI Hospitals and Clinics
200 Hawkins Dr, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
200 Hawkins Dr, Iowa City 52242
University of Iowa Hospital and Clinics
200 Hawkins Dr, Iowa City 52242
Education:
Medical School
Weill Cornell Medical College
Graduated: 1974
U Iowa Hosps-Clins
U Ia Hosp Clins
U Oxford
Weill Cornell Medical College
Graduated: 1974
U Iowa Hosps-Clins
U Ia Hosp Clins
U Oxford
Roger D Gingrich, Iowa City IA
Specialties:
Oncologist
Address:
200 Hawkins Dr, Iowa City, IA 52242
Education:
University of Oxford - Doctor of Philosophy
Cornell University, Weill Cornell Medical College - Doctor of Medicine
University of Iowa Hospitals & Clinics - Fellowship - Hematology and Oncology (Internal Medicine)
University of Iowa Hospitals & Clinics - Residency - Internal Medicine
Cornell University, Weill Cornell Medical College - Doctor of Medicine
University of Iowa Hospitals & Clinics - Fellowship - Hematology and Oncology (Internal Medicine)
University of Iowa Hospitals & Clinics - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Humanized Antibodies Against Cd3
US Patent:
7381803, Jun 3, 2008
Filed:
Jul 18, 2000
Appl. No.:
09/618380
Inventors:
George Weiner - Iowa City IA, US
Roger Gingrich - Iowa City IA, US
Brian K. Link - Coralville IA, US
J. Yun Tso - Menlo Park CA, US
Roger Gingrich - Iowa City IA, US
Brian K. Link - Coralville IA, US
J. Yun Tso - Menlo Park CA, US
Assignee:
PDL BioPharma, Inc. - Redwood City CA
Iowa Immunotherapy Investigators - Iowa City IA
Iowa Immunotherapy Investigators - Iowa City IA
International Classification:
C07K 16/30
US Classification:
53038885, 5303871, 5303873, 4241331
Abstract:
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
Bispecific Antibody Effective To Treat B-Cell Lymphoma And Cell Line
US Patent:
6129914, Oct 10, 2000
Filed:
Mar 1, 1995
Appl. No.:
8/397411
Inventors:
George Weiner - Iowa City IA
Roger Gingrich - Iowa City IA
Brian K. Link - Carlville IA
J. Yun Tso - Menlo Park CA
Roger Gingrich - Iowa City IA
Brian K. Link - Carlville IA
J. Yun Tso - Menlo Park CA
Assignee:
Protein Design Labs, Inc. - Fremont CA
International Classification:
A61K 39395, C12P 2104, C12P 2108, C07K 1600
US Classification:
4241331
Abstract:
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
Humanized Antibodies Against Cd3
US Patent:
2008002, Jan 31, 2008
Filed:
Mar 26, 2007
Appl. No.:
11/691350
Inventors:
George Weiner - Iowa City IA, US
Roger Gingrich - Iowa City IA, US
Brian Link - Coralville IA, US
J. Tso - Menlo Park CA, US
Roger Gingrich - Iowa City IA, US
Brian Link - Coralville IA, US
J. Tso - Menlo Park CA, US
Assignee:
Protein Design Labs, Inc. - Fremont CA
Iowa Immunotherapy Investigators - Iowa City IA
Iowa Immunotherapy Investigators - Iowa City IA
International Classification:
A61K 39/395, A61P 31/00, C07K 16/00
US Classification:
424133100, 530387300
Abstract:
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
Humanized Antibodies Against Cd3
US Patent:
2004005, Mar 18, 2004
Filed:
May 9, 2003
Appl. No.:
10/435299
Inventors:
George Weiner - Iowa City IA, US
Roger Gingrich - Iowa City IA, US
Brian Link - Carlville IA, US
J. Tso - Menlo Park CA, US
Roger Gingrich - Iowa City IA, US
Brian Link - Carlville IA, US
J. Tso - Menlo Park CA, US
International Classification:
A61K039/395, C12N005/06, C07K016/30
US Classification:
424/133100, 530/388800, 435/327000
Abstract:
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.